Cargando…
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
The epidermal growth factor receptor (EGFR) inhibitors such as erlotinib and gefitinib are widely used for treatment of non-small cell lung cancer (NSCLC), but they have shown limited efficacy in an unselected population of patients. The KRAS mutations, which are identified in approximately 20% of N...
Autores principales: | Park, Jieun, Cho, Yong-Hee, Shin, Wook-Jin, Lee, Sang-Kyu, Lee, JaeHeon, Kim, Taehyung, Cha, Pu-Hyeon, Yang, Jee Sun, Cho, Jaebeom, Min, Do Sik, Han, Gyoonhee, Lee, Ho-Young, Choi, Kang-Yell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345925/ https://www.ncbi.nlm.nih.gov/pubmed/30679620 http://dx.doi.org/10.1038/s41598-018-37059-8 |
Ejemplares similares
-
KYA1797K, a Novel Small Molecule Destabilizing β-Catenin, Is Superior to ICG-001 in Protecting against Kidney Aging
por: Zhu, Mingsheng, et al.
Publicado: (2022) -
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition
por: Thuru, Xavier, et al.
Publicado: (2023) -
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018) -
Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells
por: Cho, Yong-Hee, et al.
Publicado: (2020) -
KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer
por: Cho, Yong-Hee, et al.
Publicado: (2016)